BioNTech CEO says prospective 2021 vaccine output approaching 3 bln doses

BioNTech addresses the media after EMA's approval of its COVID-19 vaccine
CEO and co-founder of BioNTech, Ugur Sahin, answers journalists' questions after the European Medicines Agency (EMA) approved its COVID-19 vaccine, at the company headquarters in Mainz, Germany December 22, 2020. REUTERS/Ralph Orlowski

BERLIN, May 4 (Reuters) - German COVID-19 vaccine maker BioNTech (22UAy.DE) has continued to ramp up production allowing it to manufacture close to 3 billion doses in 2021, up from a previous target of 2.5 billion.

"Our teams did a great job to further increase the manufacturing scale to come up now with numbers reaching 3 billion doses," BioNTech's Chief Executive and co-founder Ugur Sahin said at a webcast event organised by the Financial Times.

"We are happy that we are not facing too many technical problems and keep our delivery schedules," he added.

The Mainz-based biotech company said in March that it and its U.S. partner Pfizer (PFE.N) upgraded their supply chain to produce 2.5 billion vaccine doses this year, of which 1.4 billion were already sold. read more

Reporting by Ludwig Burger, editing by Louise Heavens

Our Standards: The Thomson Reuters Trust Principles.